Nature Communications, Published online: 25 July 2026; doi:10.1038/s41467-026-75344-7 Achieving sustained response remains a challenge for patients with difficult-to-treat immune thrombocytopenia (ITP). Here, the authors report that low-dose baricitinib plus danazol may be effective for patients with difficult-to-treat ITP with acceptable safety profiles.